ClinicalTrials.gg
Not yet recruitingNCT07710612Updated Jul 17, 2026

A Phase 2 Study of ABSK043 Combined With Osimertinib

A Phase 2 interventional study of ABSK043 in combination with Osimertinib in Non-Small Cell Lung Cancer With EGFR-mutated and PD-L1 Positive, sponsored by Abbisko Therapeutics Co, Ltd. Not yet recruiting at 7 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-17.

Sponsored by Abbisko Therapeutics Co, Ltd (part of Abbisko Cayman Limited) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
72
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 90 studies testing osimertinib in Carcinoma, Non-Small-Cell Lung — 20 open to participants now, 43 under way, 8 of them phase 3. osimertinib · Carcinoma, Non-Small-Cell Lung.

Planned enrollment
36th of 90
72 · median 51
Started
2026
with 4 others
Phase 2
46 of 90
12 open now
Primary completion
2029-12
later than 42 of 42 live
Registered
91st of 90
by date

Among the 90 studies testing osimertinib in Carcinoma, Non-Small-Cell Lung, this one is the 36th largest by planned enrollment, is one of 5 that started in 2026, is one of 46 in phase 2, reaches primary completion later than 42 of the 42 other live ones, and was the 91st registered.

Carcinoma, Non-Small-Cell Lung

7,632 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

20 of the 90 studies testing osimertinib in Carcinoma, Non-Small-Cell Lung are open now, in 7 countries. Recruiting first, the newest first:

15 more — sign in →

By country, each count listing its studies:

All 20 open studies →

About osimertinib

osimertinib: first FDA approval 2015 (TAGRISSO), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 90 studies testing osimertinib in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

This is a phase 2, open-Label study to evaluate the efficacy and safety of ABSK043 Combined with Osimertinib in participants with EGFR-Mutated locally advanced or metastatic Non-Small Cell Lung Cancer

Read the detailed description

This is an open-label study with an escalation part and an expansion part. The dose escalation part will evaluate the safety, tolerability of ABSK043 in combination with Osimertinib in previously treated participants with EGFR-mutated and PD-L1 positive locally advanced or metastatic NSCLC. The expansion part will evaluate the efficacy of ABSK043 in combination with Osimertinib as first-line treatment for participants with EGFR-mutated and PD-L1 positive locally advanced or metastatic NSCLC at the one or more recommended dose(s). The safety, tolerability, and PK profile of ABSK043 in combination with Osimertinib will also be further evaluated.

Escalation Part:

The escalation part includes dose escalation cohorts and backfill cohort(s), enrolling a sufficient number with previously treated participants with EGFR-mutated and PD-L1 positive locally advanced or metastatic NSCLC.

Expansion Part:

The expansion part will enroll a sufficient number with treatment-naïve participants with locally advanced or metastatic NSCLC harboring the EGFR mutation and PD-L1 positive expression.

03

Conditions studied

  • Non-Small Cell Lung Cancer With EGFR-mutated and PD-L1 Positive
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged 18 or above, male or female.
  2. Participants must understand and voluntarily participate in this study and must have been provided for study participation.
  3. NSNLC confirmed by tissue or cytological pathology. NSCLC with a mixed histology is eligible, if adenocarcinoma is the predominant histology.
  4. Diagnosed locally advanced or NSCLC
  5. Different requirements for specific cohort:

    Dose escalation and backfill cohorts:

    1. Participants with disease in the setting, post chemoradiotherapy setting, locally advanced stage or metastatic stage, who have received at least one prior line of third-generation EGFR-TKI-based monotherapy or combination therapy and experienced disease progression.
    2. Participants must have received ≥2 prior lines of frontline systemic therapy.
    3. Documented or central laboratory test report confirms that the tumor is expression positive (TPS/TC≥1%).
    4. Documented genetic testing report confirms the presence of EGFR alteration(s) in tumor or plasma.

    Expansion cohort(s):

    1. Participants must not have received any other prior systemic cancer therapies in the locally advanced/metastatic setting for locally advanced or metastatic disease.
    2. Central laboratory test report confirms that the tumor is PD-L1 expression positive (TPS/TC≥1%).
    3. Documented genetic testing reports confirm the presence of EGFR
  6. Presence of at least one measurable tumor lesion
  7. score 0-1 at screening.
  8. The expected after the first dose is >12 weeks.

Exclusion criteria

Exclusion Criteria:

  • 1. Histological or cytological examinations suggest that NSCLC squamous cells is the predominant histology, or contains small cell lung cancer, neuroendocrine carcinoma, etc.

    2. Has a history of interstitial lung disease (ILD)/pneumonitis or active ILD 3. Spinal cord compression and unstable . 4.Any unresolved toxicities from prior systemic therapy greater than v6.0 Grade 1 at the time of starting study treatment.

    5. Participants with obvious and unstable pleural effusion, peritoneal effusion or pericardial effusion .

    6. Has a history of other malignant tumors, or currently have other malignant tumors.

    7. Participants with known infection.

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
72 participants (estimated)

Study arms

  • Experimental
    ABSK043 in combination with Osimertinib

    This is an open-label phase 2 study with an escalation part and an expansion part.

    Drug: ABSK043 in combination with Osimertinib

Interventions

  • DrugABSK043 in combination with Osimertinib

    Drug pages: PD-L1 Inhibitor ABSK043 · Osimertinib

    Three potential dose levels of ABSK043 are prespecified, and Osimertinib will be administered orally at a fixed dose of 80 mg QD in escalation cohort. Patients in dose confirmation cohort and dose expansion cohort will receive the recommended dose in dose escalation cohort and be evaluated for safety and preliminary anti-tumor activity of the combination therapy.

06

What researchers measure

Primary outcomes

  1. - Incidence of dose-limiting toxicity (DLT)

    Escalation Part

    Time frame: At the end of Cycle 1 (each cycle is 21 days)

  2. Adverse events(AEs)

    Escalation Part

    Time frame: From the time the patient signs the informed consent form throughout the study and up to 30 days (± 7 days) after the last dose of ABSK043 or Osimertinib, up to 30 months.

  3. Serious adverse events (SAEs)

    Escalation Part

    Time frame: From the time the patient signs the informed consent form throughout the study and up to 30 days (± 7 days) after the last dose of ABSK043 or Osimertinib, up to 30 months.

  4. Adverse events of special interest (AESIs)

    Escalation Part

    Time frame: From the time the patient signs the informed consent form throughout the study and up to 30 days (± 7 days) after the last dose of ABSK043 or Osimertinib, up to 30 months.

  5. Progression-free survival at 12 month

    Expansion Part

    Time frame: From the time patients receive the first dose of study drug to 12 months,assessed up to 5 years.

Secondary outcomes

  1. Maximum observed concentration(Cmax)

    Escalation Part

    Time frame: From the date of enrolment #Cycle1 Day1 to EOT visit and assessed up to 10 months.

  2. Area under the concentration-time curve area under the concentration-time curve area under the concentration-time curve (AUC)

    Escalation Part

    Time frame: From the date of enrolment #Cycle1 Day1 to EOT visit and assessed up to 10 months.

  3. Elimination half-life(t1/2)

    Escalation Part

    Time frame: From the date of enrolment #Cycle1 Day1 to EOT visit and assessed up to 10 months.

  4. Apparent volume of distribution(Vz/F)

    Escalation Part

    Time frame: From the date of enrolment #Cycle1 Day1 to EOT visit and assessed up to 10 months.

  5. Apparent oral clearance(CL/F)

    Escalation Part

    Time frame: From the date of enrolment #Cycle1 Day1 to EOT visit and assessed up to 10 months.

  6. Maximum observed concentration after multiple doses(Cmax,ss)

    Escalation Part

    Time frame: From the date of enrolment #Cycle1 Day1 to EOT visit and assessed up to 10 months.

  7. Minimum observed concentration after multiple doses(Cmin,ss)

    Escalation Part

    Time frame: From the date of enrolment #Cycle1 Day1 to EOT visit and assessed up to 10 months.

  8. Area under the concentration-time curve after multiple doses(AUCtau,ss)

    Escalation Part

    Time frame: From the date of enrolment #Cycle1 Day1 to EOT visit and assessed up to 10 months.

  9. Accumulation ratio(AR)

    Escalation Part

    Time frame: From the date of enrolment #Cycle1 Day1 to EOT visit and assessed up to 10 months.

  10. Time to maximum observed concentration(tmax)

    Escalation Part

    Time frame: From the date of enrolment #Cycle1 Day1 to EOT visit and assessed up to 10 months.

  11. Progression-Free Survival (PFS)

    Escalation Part

    Time frame: From treatment start up to 5 years

  12. Objective response rate (ORR)

    Defined as the proportion of participants achieving confirmed complete response (CR) or partial response (PR), as assessed by the investigator according to RECIST v1.1.

    Time frame: From treatment start up to 5 years

  13. Duration of response (DOR)

    Defined as the time (months) from the first documented objective response to the investigator-assessed radiographic disease progression (PD) according to RECIST v1.1 or death from any cause, whichever occurs first.

    Time frame: From treatment start up to 5 years

  14. Disease control rate (DCR)

    Defined as the proportion of participants achieving confirmed complete remission (CR) or partial remission (PR), or stable disease (SD), as assessed by the investigator according to RECIST v1.1.

    Time frame: From treatment start up to 5 years

  15. Time to progression (TTP)

    Defined as the time (months) from the first dose of study drug until the onset of radiographic disease progression (PD) as assessed by the investigator according to RECIST v1.1.

    Time frame: From treatment start up to 5 years

  16. Overall survival (OS)

    Defined as the time (months) from the first administration of study drug to death due to any cause.

    Time frame: From treatment start up to 7 years

07

Study locations

7 sites
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2026; primary completion for Dec 2029, 40 months later.

Of 317 industry-sponsored phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 59. This study's planned 40 months is close to that.

Counting every sponsor, half of 1,047 studies reached it within 48 months; a quarter within 30 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 14, 2026
First posted
Jul 17, 2026
StartEst.
Aug 31, 2026
Primary completionEst.
Dec 31, 2029
CompletionEst.
Dec 31, 2030
Last update
Jul 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07710612
Collaborators
AstraZeneca
Responsible party
Sponsor
First posted
Jul 17, 2026
Start date
Aug 31, 2026 (estimated)
Primary completion
Dec 31, 2029 (estimated)
Completion
Dec 31, 2030 (estimated)
Last update
Jul 17, 2026

Study contacts

Zan Chen
Contact
zan.chen@abbisko.com
+8613816094024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: PD-L1 Inhibitor ABSK043 · Osimertinib

Start the discussion